NEW YORK (Reuters Health) – Among patients with type 2 diabetes, those taking a once-daily extended-release formulation of glipizide are more compliant with treatment than those taking a twice-daily immediate-release formulation.
In a retrospective study based on data from a pharmacy benefit management database, Christopher M. Dezii and colleagues, from Bristol-Myers Squibb Co., Princeton, New Jersey, examined differences in adherence and persistence with prescribed therapy in patients new to once-daily glipizide gastrointestinal therapeutic system (GITS) or to twice -daily (BID) glipizide..
Patients in the GITS group had an adherence rate of 60.5% while their mean pill-count per day was 2.25, compared with 52.0% adherence in the BID group with a daily pill-count of 2, according to the report in the January issue of the Southern Medical Journal. At 12 month, persistence rates were 44.4% and 35.8% in the GITS and BID groups, respectively.
"These data suggest that dosing frequency exerts a greater impact on patient adherence and persistence than number of tablets per dose," the investigators conclude.
South Med J 2002;95:68-71.